简介：Livertransplantation（LT）isalife-savingtreatmentforpatientswithend-stageliverdiseaseandforpatientswithlivercellcancerrelatedtoliverdisease.Acuteandchronicliverdiseasesrelatedtohepatitisvirusesarebetweenthemainindicationsforlivertransplantation.Theriskofviralreinfectionaftertransplantationisthemainlimitingfactorintheseindications.Beforetheavailabilityofantiviralprophylaxis,hepatitisBvirus（HBV）recurrencewasuniversalinpatientswhowereHBVDNA-positivebeforetransplantation.ThenaturalhistoryofrecurrentHBVwasacceleratedbyimmunosuppression,anditprogressedrapidlytograftfailureanddeath.Introductionofpost-transplantprophylaxiswithimmunoglobulinalonefirst,andassociatedtoantiviraldrugslater,drasticallyreducedHBVrecurrence,resultinginexcellentlong-termoutcomes.Onthecontrary,recurrenceofhepatitisCisthemaincauseofgraftlossinmosttransplantprograms.Overall,patientandgraftsurvivalafterLTforhepatitisCvirus（HCV）-associatedcirrhosisisinferiorcomparedwithotherindications.However,successfulpretransplantorposttransplantantiviraltherapyhasbeenassociatedwithincreasedgraftandoverallsurvival.Untilrecently,thecombinationofpegylatedinterferonandribavirinwasthestandardofcareforthetreatmentofpatientswithchronichepatitisC.Highlyactiveantiviralcompoundshavebeendevelopedoverthepastdecade,thankstonewinvitrosystemstostudyHCVentry,replication,assembly,andrelease.

简介：我们应用赛生公司提供的日达仙（胸腺肽α1Tα1）治疗慢性肝炎11例,现小结如下。资料与方法一、病例选择住院患者7例、门诊4例,年龄18～27岁。病程平均5.5年。10例血清HBsAg、HBeAg

简介：